ASCO GU 2020 Prostate Cancer - Results from #20

Viewing 21-40 of 92 articles

ASCO GU 2020: Updated Results from the STOMP Trial: Targeted Therapy in the Context of Low-Volume Metastatic Prostate Cancer

ASCO GU 2020: Best of Journals Prostate Cancer: Medical Oncology

ASCO GU 2020: Best of Journals Prostate Cancer: Radiation Oncology

ASCO GU 2020: Best of Journals Prostate Cancer: Surgery

ASCO GU 2020: Contemporary Clinical Impact of Genetic and Genomic Testing in Prostate Cancer

ASCO GU 2020: Treatment Decision Making in Metastatic Prostate Cancer

ASCO GU 2020: Using Circulating Tumor DNA to Detect Neuroendocrine Prostate Cancer Genomic and DNA Methylation Changes

ASCO GU 2020: Pembrolizumab Plus Enzalutamide for Enza-Resistant Metastatic Castration-Resistant Prostate Cancer: KEYNOTE-199 Cohorts 4-5

ASCO GU 2020: Defining the Extent of Disease Using Novel Approaches: Beyond Standard Imaging

ASCO GU 2020: Implications for Adverse Effects and Development of Combination Therapies - The Effect of Deep AR Suppression with Enzalutamide or Apalutamide on Endogenous Glucocorticoids

Beyond P-Values: When Does the Clinical Impact Outweigh Statistical Significance

ASCO GU 2020: Real-World Utilization of Radium-223 for the Treatment of mCRPC: A U.S. Tertiary Oncology Center Analysis

ASCO GU 2020: Beyond P Values: When Does Clinical Impact Outweigh Statistical Significance

ASCO GU 2020: Transcriptome Profiling of NRG Oncology/RTOG 9601: Validation of a Prognostic Genomic Classifier in Salvage Radiotherapy Prostate Cancer from a Prospective Randomized Trial

ASCO GU 2020: Niraparib in Patients with mCRPC and Biallelic DNA-Repair Gene Defects: Correlative Measures of Tumor Response in Phase II GALAHAD Study

ASCO GU 2020: Circulating Tumor DNA to Detect Neuroendocrine Prostate Cancer Genomic and DNA Methylation Changes

ASCO GU 2020: STAMPEDE Trial - Comparative Quality of Life in Patients Randomized Contemporaneously to Docetaxel of Abiraterone

ASCO GU 2020: Defining Extent of Disease Using Novel Approaches - Beyond Standard Imaging

ASCO GU 2020: Implementation of Novel Tools in the Active Surveillance Pathway

ASCO GU 2020: Time to Second Progression in Patients with Metastatic Castration-Sensitive Prostate Cancer from TITAN by First Subsequent Therapy (Hormonal vs. Taxane)

1
2
3
4
5